As shown in Fig. 7a–c, mice treated with IL-10 neutralizing antibody together with cDNT showed increased plasma ALT levels, liver fat accumulation, inflammation, and NASH development. Here, IL10 is linked to metabolic dysfunction-associated steatohepatitis.